Log in to save to my catalogue

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib c...

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fde024de99b941a08e4dd670a8681016

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

About this item

Full title

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2019-09, Vol.8 (11), p.4976-4985

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation pr...

Alternative Titles

Full title

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_fde024de99b941a08e4dd670a8681016

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fde024de99b941a08e4dd670a8681016

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.2371

How to access this item